Baird Financial Group
CBAY

Baird Financial Group’s Cymabay Therapeutics CBAY Stock Holding History

Baird Financial Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-69,032
Closed -$755K – 1378
2018
Q3 		$755K Sell
69,032
-2,188
-3% -$27.2K ﹤0.01% 924
2018
Q2 		$956K Buy
71,220
+728
+1% +$9.11K 0.01% 840
2018
Q1 		$916K Sell
70,492
-36,957
-34% -$459K 0.01% 848
2017
Q4 		$989K Buy
107,449
+22,712
+27% +$194K 0.01% 827
2017
Q3 		$683K Buy
+84,737
New +$573K 0.01% 905

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Baird Financial Group's CBAY Position: Q4 2018 in Review

Baird Financial Group sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 69,032 shares — an estimated $755K sold.

Baird Financial Group first reported a position in CBAY in Q3 2017 and held it in 5 quarters. The position peaked at $989K in Q4 2017. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

  • Baird Financial Group reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Baird Financial Group sold 69,032 Cymabay Therapeutics shares in Q4 2018, an estimated $755K.
  • Baird Financial Group first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 5 quarters.
  • Baird Financial Group's Cymabay Therapeutics position peaked at $989K in Q4 2017.
  • 131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on Baird Financial Group's 13F filing for Q4 2018, filed 14 Feb 2019.